Delivery Order HT942523D0011-HT942626FE055
Award Date 7/1/26
Potential Completion Date 6/30/27
Potential Value $100K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $1.3 million firm fixed-price purchase order to Eitr Biologics, Inc., a San Diego-based biotechnology company specializing in antibody discovery and viral countermeasures. The contract, set aside for small business, focuses on sorting peripheral blood mononuclear cells from Lassa fever virus survivors to discover and produce monoclonal antibodies for subsequent assessment in in vitro and in vivo assays. This work supports the Defense Health Agency's medical...
- The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Eitr Biologics, Inc. for development of a multimodal antibody platform to extend the window of immunotherapeutic intervention on September 22, 2023, with a ceiling value of $317.6 million. The contract pursues critical evaluation of the VHH (variable domain of heavy chain antibody) as a platform medical countermeasure technology. Work is performed in San Diego, CA. The contract carries...
- The Defense Health Agency awarded a $3.93 million definitive contract to Hexamer Therapeutics Inc. for research and development services on September 29, 2023, under a firm fixed-price structure with no set-aside. The contract funds development of a self-assembling, molecular carrier vaccine platform intended for deployment during an infectious disease pandemic, under the U.S. Army Medical Research and Development Command's mission to provide medical solutions for service members and the general...
- The Defense Health Agency awarded a purchase order to Glyphic Biotechnologies, Inc., a small disadvantaged business, for $249,993.28 on April 8, 2024, to develop anti-glycan antibodies against multi-drug resistant ESKAPE wound pathogens under a Small Business Innovation Research Phase I effort. The order is a total small business set-aside with firm fixed-price terms. Work is performed in New York, New York, with completion required by November 7, 2024. The procurement addresses medical research...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of HYPERRAB 300 Unit/ML vials, with a ceiling value of $1,039.53 and a completion date of June 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the...
- The Defense Logistics Agency issued a $1,649.10 delivery order to Amerisourcebergen Drug Corp on April 8, 2026, for HYPERRAB 300 unit/mL vial 5mL pharmaceutical supply. The order is issued under the DLA Troop Support Medical IDC (SPE2DX), a $999,999,999 indefinite delivery contract running through December 2026 that supplies pharmaceutical products and medical supplies to support military healthcare programs globally. Place of performance is Conshohocken, PA. Ultimate completion date is April...
- The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 11, 2026, with a ceiling value of $8,245.50 for HYPERRAB 300 unit/mL vial 5mL. This is a firm fixed-price delivery order under the Defense Logistics Agency Troop Support Medical IDC (SPE2DX), a $999,999,999 indefinite delivery contract running through December 2026 that supplies pharmaceutical products and medical supplies to support military healthcare programs globally. Place of performance is...
- The Defense Health Agency issued a $33,997.95 delivery order to Chenkwang Science on October 1, 2025, for Biomerieux reagents, with completion by September 30, 2026, under a single-award IDC. The parent Indefinite Delivery Contract, valued at $232,645.53 and effective October 1, 2023, through September 30, 2028, encompasses a one-year base period plus four one-year option periods. The IDC was awarded without full and open competition due to the contractor's unique capabilities in supplying...
- The Defense Logistics Agency issued a $9,894.60 delivery order to AmerisourceBergen Drug Corp on March 13, 2026, for HYPERRAB 300 unit/mL vial 5mL pharmaceutical product, with ultimate completion on April 3, 2026. The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (IDC), a $999,999,999 vehicle through December 2026 that supplies pharmaceutical products and medical commodities to support military healthcare programs worldwide. Place of performance is...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on January 15, 2026, for interventional agents chemistry services, with a ceiling value of $86,902.75 and an ultimate completion date of January 14, 2027. This delivery order is issued under Sri International's single-award Interventional Agents Chemistry Services indefinite delivery vehicle ($50 million ceiling, September 2025–September 2032) with the National Institute of Allergy and...